No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Study: Radiologist Characteristics Predict Performance in Screening Mammography

Editor: What To Know

  • “Most mammograms performed in the United States are interpreted by general radiologists and not by breast subspecialty radiologists, who account for less than 10% of all radiologists,” said Andrew Rosenkrantz, MD, MPA, lead study author, professor and Director of health policy in the Department of Radiology at NYU Grossman School of Medicine and a Neiman Institute senior affiliate research fellow.
  • From this dataset, researchers found that radiologists in the West or Midwest, breast subspecialists, and those who perform diagnostic mammography were more likely to achieve acceptable performance across a range of metrics.
  • Neiman Health Policy Institute and the American College of Radiology's National Mammography Database Committee, the most influential radiologist characteristics impacting mammography interpretive performance were geography, breast sub-specialization, performance of diagnostic mammography, and performance of diagnostic ultrasound.

Screening Mammography: According to a new study, by the Harvey L. Neiman Health Policy Institute and the American College of Radiology’s National Mammography Database Committee, the most influential radiologist characteristics impacting mammography interpretive performance were geography, breast sub-specialization, performance of diagnostic mammography, and performance of diagnostic ultrasound.

Published June 22 in Radiology, the study analyzed 11 years of screening mammography performance metrics from the National Mammography Database (NMD). From this dataset, researchers found that radiologists in the West or Midwest, breast subspecialists, and those who perform diagnostic mammography were more likely to achieve acceptable performance across a range of metrics. Those who perform breast ultrasound were less likely to achieve acceptable performance across metrics.

Researchers say that despite wide variation across radiologists in the accuracy of mammographic interpretation, factors that predict performance are poorly understood.

“It was interesting that in many cases certain characteristics predicted higher performance in some areas and, at the same time, lower performance on others,” said first author Cindy Lee, MD, FACMQ, FSBI, Assistant Professor of Radiology at NYU Grossman School of Medicine. For example, radiologists who are in academic practice, are breast imagers, and with more years in practice are more likely to have higher recall rates, but they are also more likely to detect higher proportions of ductal carcinoma in situ, have higher cancer detection rates, and higher invasive cancer detection rates — critical measures for reducing breast cancer mortality. “This example highlights the importance of assessing performance across measures holistically versus individual metrics in isolation, supporting guidance in the ACR BI-RADS atlas” Dr. Lee explained.

This study has the largest sample of radiologists with verified demographic and workforce data and interpretive screening performance in the United States. Of the 1,223 radiologists studied, 31.7% of radiologists had acceptable performance for all metrics, based on external benchmarks. For each metrics individually, 52-77% of radiologists demonstrated performance in the acceptable range.

“Most mammograms performed in the United States are interpreted by general radiologists and not by breast subspecialty radiologists, who account for less than 10% of all radiologists,” said Andrew Rosenkrantz, MD, MPA, lead study author, professor and Director of health policy in the Department of Radiology at NYU Grossman School of Medicine and a Neiman Institute senior affiliate research fellow. “As the U.S. population ages and greater numbers of women comply with screening guidelines, the demand for all radiologists to interpret screening mammograms is anticipated to increase. Hence, attention to the interpretive screening performance of all radiologists is critical, and strategies to improve interpretive accuracy among generalists would be beneficial.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy